The patent application WO2017006968, related to delgocitinib, was published by the World Intellectual Property Organization (WIPO) [1]. This application is available through patent search engines like Google Patents [2].
What is Delgocitinib?
Delgocitinib is an orally administered Janus kinase (JAK) inhibitor. It targets JAK1, JAK2, JAK3, and TYK2, which are enzymes involved in signaling pathways that regulate immune responses and inflammation [3][4]. This mechanism of action makes it a potential treatment for various immune-related and inflammatory diseases [3].
What conditions can Delgocitinib treat?
Delgocitinib is being investigated for its efficacy in treating conditions such as atopic dermatitis, alopecia areata, and rheumatoid arthritis [3][5]. Its ability to modulate immune responses is key to its therapeutic potential in these autoimmune and inflammatory disorders [3].
When does the patent for Delgocitinib expire?
Patent expiry dates for pharmaceutical compounds are complex and depend on various factors, including when patents were first filed and any extensions granted. Specific patent information for delgocitinib can be found through patent databases [1][2]. DrugPatentWatch.com provides detailed patent information and expiry timelines for many drugs, including delgocitinib [6].
Who developed Delgocitinib?
Torii Pharmaceutical Co., Ltd. developed delgocitinib [3]. The patent application WO2017006968 is assigned to Torii Pharmaceutical [1].
How does Delgocitinib compare to other JAK inhibitors?
Delgocitinib is a pan-JAK inhibitor, meaning it inhibits all four JAK isoforms (JAK1, JAK2, JAK3, and TYK2) [3][4]. Other JAK inhibitors may have different selectivity profiles, targeting specific JAK isoforms, which can influence their efficacy and side effect profiles [4]. The specific selectivity of delgocitinib is central to its therapeutic application [3].
What are the clinical trial results for Delgocitinib?
Clinical trials have demonstrated delgocitinib's efficacy in improving symptoms of atopic dermatitis, reducing disease activity in rheumatoid arthritis, and showing promise in treating alopecia areata [3][5]. These results support its potential as a treatment option for these conditions.
What are the potential side effects of Delgocitinib?
As a JAK inhibitor, potential side effects can include increased risk of infections, changes in blood counts, and other immune-related effects [4]. Specific side effects observed in clinical trials for delgocitinib are detailed in study reports and regulatory filings [3][5].
What is the regulatory status of Delgocitinib?
Delgocitinib has received approvals in some regions for specific indications. For example, it is approved in Japan for atopic dermatitis and alopecia areata [3]. Regulatory review processes in other regions are ongoing or have been completed for different indications.
Where can I find more information about Delgocitinib patents?
Patent information for delgocitinib, including the WO2017006968 application, can be accessed through patent search engines such as Google Patents [2]. For comprehensive and up-to-date patent data, including expiry dates and any legal challenges, resources like DrugPatentWatch.com are available [6].
Sources:
[1] WIPO. "WO2017006968." https://patents.google.com/patent/WO2017006968A1/en
[2] Google Patents. "WO2017006968." https://patents.google.com/patent/WO2017006968A1/en
[3] Torii Pharmaceutical Co., Ltd. "Delgocitinib." https://www.torii.co.jp/en/rd/pipeline/delgocitinib.php
[4] National Center for Biotechnology Information. "Delgocitinib." https://pubchem.ncbi.nlm.nih.gov/compound/Delgocitinib
[5] ClinicalTrials.gov. "Delgocitinib." https://clinicaltrials.gov/ct2/results?cond=&term=delgocitinib
[6] DrugPatentWatch.com. https://www.drugpatentwatch.com/